Record Number of Accepted Abstracts Highlight Benefits of RECELL System and Reinforce Rapid Adoption by Surgeons to Advance Burn Care Record Number of Accepted Abstracts Highlight Benefits of RECELL S
VALENCIA, Calif. and MELBOURNE, Australia, March 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 25, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and
AVITA Therapeutics, Inc. (RCEL) CEO Mike Perry on Q2 2021 Results - Earnings Call Transcript
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 11, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializi
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 03, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a tech
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 28, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a tech
AVITA Medical, Inc. (RCEL) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
VALENCIA, Calif. and MELBOURNE, Australia, Dec. 28, 2020 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a tech
VALENCIA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that

AVITA: COVID-19's Impact

11:57am, Tuesday, 17'th Nov 2020
AVITA's existing FDA-approved product is growing to become the standard of care in a $200 million market. The COVID-19 pandemic has been particularly disruptive for AVITA.
AVITA Therapeutics, Inc. (RCEL) CEO Michael Perry on Q1 2021 Results - Earnings Call Transcript
AVITA Therapeutics, Inc. (RCEL) CEO Michael Perry On Q3 2020 Results - Quick Version Earnings Call Transcript.
VALENCIA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE